# VE303 for Treatment of Hepatic Encephalopathy (HE)

> **NCT04899115** · PHASE2 · COMPLETED · sponsor: **Patricia Bloom** · enrollment: 19 (actual)

## Conditions studied

- Cirrhosis
- Hepatic Encephalopathy

## Interventions

- **DRUG:** Placebo
- **DRUG:** VE303
- **DRUG:** oral vancomycin

## Key facts

- **NCT ID:** NCT04899115
- **Lead sponsor:** Patricia Bloom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-08-30
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04899115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04899115, "VE303 for Treatment of Hepatic Encephalopathy (HE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04899115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*